Related Experiment Video

Updated: Jun 16, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD

Stephanie J Leuenroth1, Natasha Bencivenga, Halima Chahboune

  • 1Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06511, USA.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|February 9, 2010
PubMed

Insights

Triptolide treatment significantly reduced kidney cyst development in a Pkd1-floxed inducible mouse model of autosomal dominant polycystic kidney disease (ADPKD). This small molecule improved renal function, showing promise for short-term ADPKD drug studies.

Area of Science:

  • Genetics and Molecular Biology
  • Nephrology
  • Pharmacology

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of kidney failure, driven by mutations in Pkd1 or Pkd2 genes.
  • Rodent models are crucial for understanding ADPKD cystogenesis and developing new therapeutic strategies.

Purpose of the Study:

  • To evaluate the therapeutic potential of the small molecule triptolide in an inducible Pkd1-floxed mouse model of ADPKD.
  • To assess the efficacy of triptolide in reducing cyst formation and improving renal function in this ADPKD model.

Main Methods:

  • Utilized a Pkd1-floxed inducible mouse model (Pkd1(flox/flox);Mx1Cre) for studying ADPKD.
  • Administered triptolide or vehicle to mice following Pkd1 deletion to analyze cyst development.
  • Assessed kidney cyst burden, microcyst formation, and blood urea nitrogen (BUN) levels.

Main Results:

  • Triptolide treatment significantly reduced the number of kidney cysts and microcysts in Pkd1-deficient mice.
  • Improved renal function, indicated by lower BUN levels, was observed in triptolide-treated groups.
  • A 6-month study revealed minimal kidney cysts but severe liver cysts and fibrosis in Pkd1-deficient mice.

Conclusions:

  • The Pkd1(flox/flox);Mx1Cre model is suitable for short-term drug efficacy studies in ADPKD.
  • Long-term studies using this model may be complicated by significant liver cystogenesis and fibrosis, potentially affecting drug metabolism.
Abstract

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...